Itraconazole Synthesis Essay

Understanding the mechanism(s) of action of different antimicrobial agents is an important prerequisite to understanding mechanisms of resistance. In fact, in many cases an elucidation of resistance mechanisms has allowed or enhanced our understanding of specific mechanisms of action. We therefore combine our discussions of mechanisms of action and resistance to individual antimicrobial classes, although the bulk of our attention is focused on mechanisms of resistance. Readers interested in a more in-depth discussion of the mechanisms of action of different antifungal agents are referred to thorough reviews (35, 36, 48, 52, 118, 124).

Antimicrobial Agents Affecting Fungal Sterols

The three major groups of antifungal agents in clinical use, azoles, polyenes, and allylamine/thiocarbamates, all owe their antifungal activities to inhibition of synthesis of or direct interaction with ergosterol. Ergosterol is the predominant component of the fungal cell membrane (104).

Azole-based antimycotic agents.

(i) Mechanism of action.

The first reports of the antifungal properties of N-substituted imidazoles were published in the late 1960s (55, 125). These original compounds, such as miconazole and econazole, and those that followed, such as ketoconazole, fluconazole, and itraconazole, proved to be important drugs for combating human fungal infections. The clinical efficacy and safety of fluconazole in particular has resulted in widespread use. The resultant emergence of resistance to azoles has intensified the search for new compounds that are active against resistant organisms (29, 47, 58, 76, 93, 94, 106, 129, 133, 136, 156). A review of the abstracts presented at the 1995 and 1996 Interscience Conference on Antimicrobial Agents and Chemotherapy revealed that 10 azole-related agents are currently under development for the treatment of fungal infections.

Ergosterol serves as a bioregulator of membrane fluidity and asymmetry and consequently of membrane integrity in fungal cells (100). Integrity of the cell membrane requires that inserted sterols lack C-4 methyl groups. Several lines of evidence suggest that the primary target of azoles is the heme protein, which cocatalyzes cytochrome P-450-dependent 14α-demethylation of lanosterol (51). Inhibition of 14α-demethylase leads to depletion of ergosterol and accumulation of sterol precursors, including 14α-methylated sterols (lanosterol, 4,14-dimethylzymosterol, and 24-methylenedihydrolanosterol), resulting in the formation of a plasma membrane with altered structure and function. The more recent triazole derivatives, such as fluconazole, itraconazole, and voriconazole (a triazole in development), owe their antifungal activity at least in part to inhibition of cytochrome P-450-dependent 14α-sterol demethylase (121). Compelling data in support of this mechanism of action comes from studies in which Geber et al. (34) cloned the structural genes encoding the 14α-methyl sterol demethylase (ERG11) and the Δ5,6 sterol desaturase (ERG3) from C. glabrata and used these cloned genes to create knockout mutants of each gene individually and both genes together. Phenotypic analysis revealed that the ERG3 deletion mutant remained susceptible to fluconazole and itraconazole. In contrast, the ERG11 deletion mutant and a double mutant in which both genes were deleted were resistant to 100, 16, and 2 μg of fluconazole, itraconazole, and amphotericin B per ml, respectively. These data suggest an inhibitory interaction between azoles and 14α-demethylase.

Although more recent azole antifungals are 14α-demethylase inhibitors, there exists a heterogeneity of action among these antifungals (6, 37, 131). The earlier imidazole derivatives (such as miconazole, econazole, and ketoconazole) have a complex mode of action, inhibiting several membrane-bound enzymes as well as membrane lipid biosynthesis (for a review, see Sheehan et al. [125] and Hitchcock and Whittle [52]). An accumulation of zymosterol and squalene synthesis was observed when C. albicans cells were treated with voriconazole (121). It is unclear whether the accumulation of these intermediates results from voriconazole interaction with various (non-14α-demethylase) enzymes involved in ergosterol synthesis or from secondary effects of 14α-demethylase inhibition. Azole activity may also vary with the genus tested. In addition to inhibiting the 14α-demethylase in Cryptococcus neoformans, fluconazole and itraconazole affect the reduction of obtusifolione to obtusifoliol, which results in the accumulation of methylated sterol precursors (39, 140). Mammalian cholesterol synthesis is also blocked by azoles at the stage of 14α-demethylation; however, the dose required to effect the same degree of inhibition is much higher than that required for fungi (51, 142, 143). For example, Hitchcock et al. (54) showed that voriconazole had a 50% inhibitory concentration of 7.4 μM against P-450-dependent 14α-sterol demethylase (P-450DM) of rat liver cholesterol. In contrast, the 50% inhibitory concentration of this antifungal agent against fungal P-450DM was as low as 0.03 μM (about 250-fold more active against the fungal enzyme than against the mammalian enzyme). The clinical effects of inhibition of human sterol biosynthesis are most prominently seen with ketoconazole. Figure ​2 is a summary of the ergosterol biosynthetic pathway showing sites of action of antifungal agents.

FIG. 2

Ergosterol biosynthetic pathway. Steps at which various antifungal agents exert their inhibitory activities are shown. TERB, terbinafine; FLU, fluconazole; ITRA, itraconazole; VOR, voriconazole.

(ii) Mechanisms of resistance to azoles.

As noted above, there are as yet no reports of modification of azole antimicrobials as a mechanism of resistance. Resistant strains therefore either exhibit a modification in the quality or quantity of target enzyme, reduced access to the target, or some combination of these mechanisms. These mechanisms are discussed in detail below and are summarized in Fig. ​3 and Table ​2.

FIG. 3

Mechanisms by which microbial cells might develop resistance. 1, The target enzyme is overproduced, so that the drug does not inhibit the biochemical reaction completely. 2, The drug target is altered so that the drug cannot bind to the target. 3, The...

TABLE 2

Biochemical basis of azole resistance

(a) Modification of target. Several lines of evidence implicate a modification in the quantity or quality of 14α-demethylase in the expression of resistance to azole antifungal agents. A recent study examined the biochemical mechanisms for resistance to fluconazole by comparing sterol composition, fluconazole accumulation, and inhibition of 14α-demethylase by fluconazole in two clinical C. krusei strains (expressing intrinsic resistance to fluconazole) and a susceptible C. albicans isolate (101). No significant differences in the sterol content of C. krusei and C. albicans were detected (ergosterol was the major sterol in both species). Studies performed on cell extracts indicated that the concentration of fluconazole required to inhibit the synthesis of ergosterol by 50% was approximately 24- to 46-fold higher in C. krusei than in C. albicans, suggesting that affinity of the target enzyme is different in the two species (101). A comparison of fluconazole accumulation by C. albicans and C. krusei indicated that fluconazole accumulation in the first 60 min was similar in all study strains. However, analysis after 90 min of incubation revealed that C. krusei accumulated 60% less fluconazole than did C. albicans, implicating active efflux in the fluconazole resistance expressed by these C. krusei strains (see below). The potential coexistence of two resistance mechanisms precludes a precise calculation of the level of resistance contributed by the low-affinity 14α-demethylase.

Other studies have implicated altered 14α-demethylase in resistance to azoles. Reduced susceptibility of C. albicansB41628 (isolated from a patient with chronic mucocutaneous candidiasis who relapsed following an extended period of treatment with ketoconazole) to miconazole, ketoconazole, itraconazole, and fluconazole was attributed to differences in the microsomal cytochrome P-450 enzyme. Analysis of carbon monoxide (CO) difference spectra of microsomes from this strain revealed that it contained cytochrome P-450 with a Soret peak different from that characteristic of the cytochrome in azole-susceptible cells (127, 128). Additionally, the enzyme had a low binding affinity for azole antifungals (144). Whether the altered 14α-demethylase is solely responsible for the level of resistance observed in this strain is unclear, since C. albicansB41628 is a clinical isolate and the contribution of other resistance mechanisms to the reduced susceptibility of this isolate cannot be excluded (53).

Overexpression of 14α-demethylase has also been implicated as a mechanism of resistance to azole antifungals. Vanden Bossche et al. (141) characterized an azole-resistant C. glabrata strain and showed that its ergosterol content was increased compared with that of the pretreatment isolate. This increase was accompanied by a decrease in susceptibility to both azoles and amphotericin B. The increase in ergosterol synthesis was attributed to an elevated microsomal P-450 content in the resistant strain, suggesting an overexpression of the enzyme. Although the intracellular content of fluconazole in the resistant strain was 1.5- to 3-fold lower than that in the pretreatment isolate, suggesting active efflux of this antifungal, the amount of itraconazole retained by the resistant strain did not differ from that found in the pretreatment isolate (141). This finding suggests that the increased P-450 levels were responsible for the cross-resistance to these two triazoles. The scarcity of clinical isolates in which overproduction of 14α-demethylase has been observed, the fact that this phenomenon was observed in C. glabrata only, and the finding that other resistance mechanisms may be operative in the same strain suggest that overexpression of target enzyme plays only a limited role in clinical resistance to the azoles.

White (151) investigated the target enzyme (Erg11p) in the C. albicans series (which consists of 17 isolates obtained from the same patient over a 2-year period) described by Redding et al. (114) by using biochemical and molecular techniques. Testing the susceptibility of Erg11p to fluconazole in cell extracts revealed that a substantial decrease occurred in isolate 13, corresponding to resistance development. To determine whether the ERG11 gene acquired any alterations in response to drug pressure, this gene was sequenced. Sequence analysis identified a single point mutation that resulted in a single-amino-acid substitution (R467K) (152). This substitution resides between two residues known to be involved in interactions with the heme moiety in the active site of the enzyme. A similar point mutation (T315A) that alters the susceptibility of the target enzyme has been observed in close proximity to the active site of this enzyme in C. albicans (72). A second significant change observed in the ERG11 gene of the resistant isolate was reported by White (152), namely, loss of allelic variation in the ERG11 promoter and in the downstream THR1 gene (which encodes homoserine kinase, which is involved in threonine synthesis). Although these changes may account for resistance development, they are not the only factors involved (see below).

(1) Correlation with antibacterial resistance. Modification of enzymes that serve as targets for antibacterial action is a well-characterized mechanism of resistance to β-lactam antimicrobials. For example, the creation of mosaic penicillin-binding proteins (PBPs) through homologous recombination is the primary mechanism of resistance to penicillin in Streptococcus pneumoniae and is an important mechanism of resistance to penicillin in Neisseria gonorrhoeae (25). In these instances, PBPs are modified by splicing in segments of PBP genes from more resistant bacteria that are taken up by the pathogenic bacteria through the process of natural transformation. Point mutations in PBPs associated with decreased susceptibility to penicillin or its derivatives have also been described in several bacterial species, including Staphylococcus aureus and Enterococcus faecium (44, 158).

Resistance resulting from increased expression of the target enzyme has also been described in bacteria. It is well established that penicillin resistance expressed by Enterococcus hirae (and E. faecium) can be increased from roughly 4 to 64 μg/ml in association with increased expression of low-affinity PBP5 (28). Further increases in the MIC of penicillin for these strains appear to require additional mutations within the pbp5 gene itself (158). Overexpression of target enzyme has also been described as a primary mechanism of resistance to the β-lactam–β-lactamase inhibitor combinations (28). Overexpression of β-lactamase enzyme may overwhelm the amount of β-lactamase inhibitor entering the periplasmic space, resulting in increased levels of resistance. Mutations within the β-lactamases themselves, resulting in decreased affinity for the inhibitor molecule, have also been implicated in resistance to these agents (157).

(b) Active efflux. Considerable evidence has now been accumulated to suggest that active efflux is an important mechanism of resistance to azole antifungals. Recent studies indicate that fungi possess at least two efflux systems: (i) proteins belonging to the major facilitator superfamily (MFS) and (ii) ATP-binding cassette (ABC) superfamily of proteins. The MFS drug efflux proteins are associated with the transport of structurally diverse compounds and account for a range of resistance to toxic compounds in microorganisms (60). An example of MFS protein associated with drug resistance in Candida is BENr (CaMDR1), which is implicated in resistance to several drugs, including benomyl, methotrexate, and fluconazole. The ABC superfamily of proteins bind ATP, which is essential for substrate transport, through a highly conserved amino acid sequence (known as the binding cassette) (60). Four families of ABC transporters have been identified in Saccharomyces cerevisiae (MDR, CFTR, YEF, and PDR). These transporters have a common four-core domain structure (49) consisting of two integral membrane domains that span the membrane multiple times and two ATP-binding cytoplasmic domains that couple ATP hydrolysis to substrate transport (60). To date, eight genes for ABC transporters have been identified in Candida. An example of an ABC transporter found in both Candida and, more recently, in Cryptococcus neoformans is CDR1, which is involved in resistance to fluconazole and other azoles. The gene encoding this transporter was cloned by Prasad et al. (111) and appears to be similar in structure to human P-glycoprotein, which functions as a multidrug pump and is associated with resistance to a number of chemotherapeutic agents in neoplasms (40). Recently, Walsh et al. (146) provided evidence that C. albicans may possess one or more additional genes encoding ATP-binding cassette MDR-like proteins that are distinct from CDR1, which could participate in the development of azole resistance. In this regard, five CDR genes (CDR1 to CDR5) which belong to the PDR family have been identified in C. albicans (88, 117, 151). Additionally, one member each of the MDR, CFTR, and YEF families were identified (HST6, YCF1, and ELF1, respectively).

Evidence implicating drug efflux as a mechanism of resistance in Candida species has been forthcoming recently. Parkinson et al. (103) compared pretreatment (susceptible) and posttreatment (resistant) isolates of C. glabrata and showed that while no change in sterol biosynthesis between these two isolates was observed, the resistant isolate accumulated less fluconazole than the susceptible one did. The reduced ability of the resistant strain to accumulate fluconazole was a consequence of energy-dependent drug efflux (103). In an extension of these studies, Hitchcock and coworkers examined the mechanism of resistance to azoles in C. albicans, C. glabrata, and C. krusei by using the fluorescent dye rhodamine 123 (Rh123), which is known to be transported by a number of MDR (multidrug-resistant) organisms (18). Their results showed that resistant isolates accumulated less Rh123 than susceptible cells did. Furthermore, active efflux of Rh123 was observed in azole-resistant isolates of C. albicans and C. glabrata, consistent with the activity of an MDR transporter. The efflux mechanism associated with movement of Rh123 appears to play a role in azole resistance in C. glabrata but not in C. albicans, suggesting that azole resistance in C. albicans may be mediated by an alternative efflux pump (74).

Sanglard et al. (123) studied a set of 16 sequential C. albicans isolates obtained from five AIDS patients. The strains were selected on the basis of increasing fluconazole resistance following prolonged treatment. In some resistant strains, decreased accumulation of fluconazole was associated with up to a 10-fold increase in the mRNA levels of the CDR1 gene. Other resistant isolates overexpressed mRNA from the gene encoding BENr (CaMDR1) and had normal levels of CDR1 mRNA. Data from this study suggests that CDR1 is involved in the export of several azole derivatives (including fluconazole, itraconazole, and ketoconazole) while BENr confers resistance specifically to fluconazole.

Redding et al. (114) studied a series of 17 C. albicans isolates cultured from a patient with recurrent episodes of oropharyngeal candidiasis who required progressively higher doses of fluconazole to control the infection. Over a 2-year period, the patient experienced 15 relapses, each of which was treated with fluconazole. Isolates from the early relapses had fluconazole MICs of <8 μg/ml, and the infection responded to fluconazole (100 mg/day). Fluconazole MICs for subsequent isolates rose steadily to 64 μg/ml, requiring progressively greater doses of fluconazole to produce a clinical response. Fluconazole was ineffective after the 14th relapse. This is shown graphically in Fig. ​4, in which the minimum effective dose of fluconazole at each relapse is plotted against the MIC for the isolate from that episode. The approximate breakpoints suggested by these data correlate roughly with achievable levels of fluconazole in blood: 100 mg/day produces peak concentrations of approximately 6 μg/ml in serum, 400 mg/day produces peak concentrations of 20 to 30 μg/ml, and the linear pharmacokinetics of fluconazole would predict concentrations of 40 to 60 μg/ml in serum at 800 mg/day. Analysis of all isolates by contour-clamped homogeneous electric field electrophoresis confirmed the persistence of the same C. albicans strain throughout all infectious episodes (114).

FIG. 4

Relationship between MIC, fluconazole dose, and emergence of resistance in oropharyngeal candidiasis. ○, MIC of fluconazole for the clinical isolate; ■, effective daily dose of fluconazole. MICs are represented on the secondary y axis,...

The sterol content did not differ between susceptible and resistant isolates in this collection (37a), suggesting that the mechanism(s) of resistance does not involve alteration in sterol composition. White (151) recently examined the expression of several genes of interest in all 17 of these isolates, including ERG16 (encoding 14-demethylase), MDR1 (encoding a member of the MFS), and CDR1 (encoding an ABC transporter), as well as other genes potentially involved in resistance. A number of interesting findings were reported (Fig. ​4): (i) MDR1 expression was increased early in the series, while the CDR1 mRNA level was increased only in the final isolates; (ii) ERG16 signal increased toward the end of the series; (iii) increases in mRNA levels of ERG16 and CDR1 correlated with increased resistance to ketoconazole and itraconazole but not to amphotericin B; and (iv) no changes in the mRNA signals for genes encoding members of the YEF and CFTR gene families (members of the ABC transporter family) were detected in the series, and no expression of ERG1 and ERG7 (genes involved in the ergosterol biosynthetic pathway) was detected (151). These data suggest that high-level azole resistance, at least in this series of isolates, results from the contributions of several mechanisms. They also suggest that prolonged exposure of a strain to one azole may lead to overexpression of genes, such as ERG16 and CDR1, that result in cross-resistance to other azoles.

The general availability of such a set is rare, and Redding and colleagues are to be commended for preserving these isolates and making them available to the scientific community for use as a tool in the investigation of resistance mechanisms as well as for preclinical evaluation of antifungals under development (9, 121).

(1) Correlation with antibacterial resistance. Membrane pumps involved in the efflux of antimicrobials are well described in many different species of bacteria. Among the best characterized of the systems involving multidrug membrane pumps is that regulated by the mar (multiple antibiotic resistance) gene locus found in Escherichia coli. Increased expression of mar-stimulated membrane pumps has been associated with resistance to chloramphenicol and tetracycline, as well as other compounds (20). Multidrug efflux pumps have also been implicated in resistance to β-lactams in Pseudomonas aeruginosa and fluoroquinolones in Staphylococcus aureus (79, 96). Similar to the situation in fungi, these pumps may combine with other resistance mechanisms (such as mutations in DNA gyrase genes) to yield higher levels of resistance than would be achievable with either mechanism alone.

(2) Alteration in membrane composition. Interactions between sterols and phospholipids in the cytoplasmic membrane affect membrane fluidity and asymmetry (104) and consequently influence the transport of materials across the membranes. A decrease in the amount of drug taken up by the fungal cell may result from changes in the sterol and/or the phospholipid composition of the fungal cell membrane. Using cerulenin as a lipid modulator, Mago and Khuller (83) demonstrated that altered phospholipids and fatty acid profiles affected C. albicans cell permeability and rendered the cells more resistant to miconazole. Hitchcock et al. (53) showed that an azole- and polyene-resistant C. albicans mutant had a larger lipid content and lower polar-lipid-to-neutral-lipid ratio than did strains susceptible to azoles. However, the most significant change in the lipid of the resistant strain was in the membrane sterol pattern, where ergosterol was replaced by methylated sterols, such as methylfecosterol. The authors hypothesized that an altered membrane sterol pattern is responsible for the doubly resistant phenotype observed in this strain (52).

Although alteration in the sterol pattern could explain the resistance mechanism in certain fungal strains (particularly in cases where ergosterol is replaced by fecosterol), we were unable to demonstrate a correlation between the sterol composition of C. albicans and resistance to azoles and polyenes. Two strain sets of C. albicans were analyzed for their sterol pattern: the first set was obtained from David Kerridge (University of Cambridge, Cambridge, England) and consisted of seven isolates that differ in their susceptibility to azoles and polyenes, while the second consisted of two clinical C. albicans isolates with different susceptibilities to fluconazole. Thin-layer and gas-liquid chromatography analyses showed that the major sterol present in all the strains tested was ergosterol (data not shown). Lower levels of lanosterol, obtusifoliol, 4,14-dimethylzymosterol, and squalene were also detected. Comparison of the sterol pattern between these resistant and susceptible strains revealed no correlation between sterol composition and susceptibility to antifungals (unpublished data). Therefore, resistance to azoles and/or polyenes in these strains is attributable to another mechanism(s) not related to the sterol pattern.

(1) Correlation with antibacterial resistance. Permeability barriers conferred by cytoplasmic membranes have been implicated in the natural resistance of anaerobic bacteria to the activity of aminoglycosides because aminoglycoside transport across the cytoplasmic membrane is an oxygen-dependent process. The intrinsic resistance of enterococci to aminoglycosides has also been hypothesized to be the result of the essentially anaerobic metabolism of these species (77).

The presence of an outer membrane in gram-negative bacteria has offered a much more varied array of opportunities for mutation to development of resistance to antibacterial compounds. Imipenem resistance in P. aeruginosa results from a combination of decreased expression of outer membrane protein D2 (a porin through which imipenem traverses the outer membrane) and increased expression of the chromosomal AmpC β-lactamase (81). Neither mutation by itself results in resistance to imipenem. Membrane changes in concert with β-lactamase production have also been implicated as mechanisms of resistance to cefepime and cefoxitin (80, 102). Vancomycin resistance in all aerobic gram-negative rods has also been attributed to the exclusion of the vancomycin molecule by the bacterial outer membrane. This exclusion is presumably based on the size of vancomycin rather than the absence of a specific porin.

(i) Mechanism of action.

From the 1950s until the discovery of the azoles, polyene antifungal agents such as amphotericin B represented the standard of therapy for systemic fungal infections (132). There is an association between polyene susceptibility and the presence of sterols in the plasma membrane of the cells. All organisms susceptible to polyenes, e.g., yeasts, algae, and protozoa, contain sterols in their outer membrane, while resistant organisms do not (97). The importance of membrane sterols for polyene activity is also supported by earlier studies, where it was shown that fungi can be protected from the inhibitory action of certain polyenes by the addition of sterol to the growth medium (41, 73, 159). It was suggested that this effect is due to a physicochemical interaction between added sterols and the polyenes, which prevents the drug from binding with the cellular sterols. The interaction between the sterols and polyenes is further supported by direct spectrophotometric evidence that adding sterols to aqueous solutions of the polyene filipin or nystatin decreases the UV absorbance significantly (73), suggesting a direct interaction between the added sterol and the antifungal agent (69, 98).

For larger polyenes, such as amphotericin B, it has been proposed that the interaction of the antifungal with membrane sterol results in the production of aqueous pores consisting of an annulus of eight amphotericin B molecules linked hydrophobically to the membrane sterols (22, 56) (Fig. ​5). This configuration gives rise to a pore in which the polyene hydroxyl residues face inward, leading to altered permeability, leakage of vital cytoplasmic components, and death of the organism (66, 67). The fatty acyl composition of the phospholipids has also been implicated in polyene susceptibility of yeast (57, 112, 113, 144). In addition, killing of C. albicans has been attributed to oxidative damage caused by polyenes (43, 137). The reader is referred to the review by Bolard and Milhaud (11) for a full discussion of the interaction of polyenes with lipids.

FIG. 5

Schematic representation of the interaction between amphotericin B and cholesterol in a phospholipid bilayer. (A) The conducting pore is formed by the end-to-end union of two wells or half pores. Adapted from reference 21 with permission of the publisher....

Although amphotericin B is the most effective antifungal drug available, its narrow therapeutic index continues to limit its clinical utility (17, 33, 82, 154). To reduce untoward effects, amphotericin B has been formulated in liposomes to allow the transfer of higher doses of amphotericin B with less toxicity to mammalian cells (62, 105). Several amphotericin B liposomal preparations have been developed, including ABELCET, Amphoteck, and AmBisome. A liposomal preparation of nystatin, a polyene antifungal agent (Nyotran), is currently undergoing preclinical and clinical evaluation (145). It is hypothesized that once amphotericin B is incorporated into liposomes, it may participate in a selective transfer mechanism, which involves its transfer from the “donor” liposome to the ergosterol-containing “target” in the fungal cell membrane aided by the fungal and/or host phospholipases (62).

(ii) Mechanism of resistance to polyenes.

Despite more than 30 years of clinical use, resistance to polyene antibiotics, such as amphotericin B and nystatin, is rare, with resistant isolates being confined mostly to the less common species of Candida, such as C. lusitaniae, C. glabrata, and C. guilliermondii (84). Fryberg (31) suggested that development of resistance occurs by selection of naturally occurring resistant cells, present in small numbers in the population. These naturally resistant cells produce modified sterols that bind nystatin with lower affinity. The growth rate in the presence of nystatin is therefore dependent upon the normal growth rate (in the absence of nystatin) and the rate at which nystatin causes cell membrane damage. This latter rate is presumed to be a function of the affinity of nystatin for the membrane sterols: the greater the nystatin-sterol affinity, the greater the rate of membrane damage. As a corollary, one would expect each resistant strain to exhibit slower growth than its more susceptible parent. A difference between resistant and susceptible strains was in fact observed (31). The fact that resistance to polyenes is gradually lost after serial passage on media devoid of nystatin presumably represents repopulation of the culture by cells producing sterols with a higher affinity for nystatin. The molecular genetics underlying these shifts in sterol content are not well worked out. Athar and Winner (4), however, have suggested that resistance results from mutation rather than selection.

Most of our knowledge of the mechanisms of resistance to polyenes in fungal species has come from studies using mutants generated by (i) growing cells in the presence of increasing concentrations of antifungal agents (multistep mutants), (ii) exposing the cells to a gradient concentration (4), or (iii) creating mutants by one-step mutation with mutagenic agents (45). Hamilton-Miller (46) proposed a “biochemical” hypothesis that resistance arises due to changes, either quantitative or qualitative, in the sterol content of the cells. According to this hypothesis, resistant cells with altered sterol content should bind smaller amounts of polyene than do susceptible cells. This decreased binding of polyenes in C. albicans mutants could be attributed to (i) a decrease in the total ergosterol content of the cell, without concomitant changes in sterol composition; (ii) replacement of some or all of the polyene-binding sterols by ones which bind polyene less well, e.g., substitution of ergosterol, cholesterol, or stigmasterol by a 3-hydroxy or 3-oxo sterol (88); or (iii) reorientation, or masking, of existing ergosterol, so that binding with polyenes is sterically or thermodynamically less favored.

Different investigators have furnished evidence in support of all of these possibilities. Capek et al. (14) demonstrated that development of inducible resistance (induced by adaptation mechanism) in a strain of C. albicans was accompanied by a decrease in the ergosterol content of the cells. This decrease in ergosterol content was due not to enzymatic degradation of preformed ergosterol but to inhibition of its synthesis. Similarly, Dick et al. (24) studied 27 polyene-resistant C. albicans isolates obtained from neutropenic patients and showed that these strains had a 74 to 85% decrease in their ergosterol content. Thus, decreased ergosterol content may lead to decreased susceptibility to polyenes.

Fryberg (31) tested a number of resistant Candida strains and showed that incrementally more resistant isolates possessed principal sterols arising from blockage of the biosynthetic pathway (leading to ergosterol) at successively earlier stages. They reported that cultures possessing Δ8-sterols are more resistant to polyenes than those possessing Δ7-sterols, which, in turn, are more resistant than those possessing Δ5,7-sterols. Kelly et al. (65) compared the susceptibility and sterol pattern of two Cryptococcus neoformans (pre- and posttreatment) isolates from an AIDS patient who failed antifungal therapy. These authors observed a correlation between resistance to amphotericin B and sterol pattern. The resistant, posttreatment isolate had a defect in Δ8,7-sterol isomerase, leading to accumulation of ergosta-5,8,22-dienol, ergosta-8,22-dienol, fecosterol, and ergosta-8-enol, with a concomitant depletion of ergosterol, the major sterol in the susceptible pretreatment isolate. In a recent study, Mbongo et al. (85) provided further evidence that the mechanism of amphotericin B resistance in Leishmania donovani involves the substitution of another sterol for ergosterol in the cell membrane. This substitution is associated with a change in membrane fluidity and a lower affinity of amphotericin B for such modified membranes.

The role played by cell wall components in affecting the interaction of polyenes with their primary site of action, the cytoplasmic membrane, was studied extensively by Kerridge and coworkers (32, 68). These authors compared the polyene susceptibility of exponential- and stationary-phase candidal cells and showed that stationary-phase cells were more resistant than exponential-phase ones. This observation was attributed to the fact that in the exponential-phase cells, breakdown and resynthesis of cell wall constituents occurs at a high rate, resulting in improved polyene access to the cell membrane. In contrast, stationary-phase cells would be expected to break down and synthesize cell wall at a much lower rate (68).

In the early 1970s, Capek and Simek (13) reported on the degradation of nystatin by an induced enzyme system elicited by dermatophytic fungi. No other study has confirmed this finding. It is therefore considered unlikely that drug modification represents a prominent mechanism of resistance to polyene antimicrobial agents. Furthermore, since polyenes do not require entrance into the cell, efflux mechanisms are unlikely to be involved in resistance development.

Limited numbers of studies have addressed the genetic basis of polyene resistance and have focused mainly on Saccharomyces cerevisiae. Molzahn and Woods (92) reported the isolation and characterization of S. cerevisiae mutants (n = 103) which were resistant to polyenes including nystatin, filipin, and pemaricin. The mutants were allocated to four unlinked genes, pol1, pol2, pol3, and pol5. These authors found a correlation between the polyene used for mutant isolation and (i) the extent of cross-resistance and (ii) the selection of mutants with mutations at particular pol genes. Analysis of sterols found in the parent and mutants revealed that ergosterol and 24,(28)-dehydroergosterol were predominant in the wild type. In contrast, the latter sterol was not detected in any of the mutants, while ergosterol was lacking in the pol2 mutant and present at only very low levels in the pol3 mutant. Although the interaction between the pol genes is unknown, derived data obtained by using UV absorption spectra suggested that these mutants have an epistatic relationship, i.e., that they act in series rather than parallel (92).

(a) Correlation with antibacterial resistance. Since little is known about the mechanisms by which fungi alter their ergosterol content in association with polyene resistance, it is difficult to draw parallels with antimicrobial resistance mechanisms. Insofar as the mechanism of polyene action involves direct interaction with a structural cellular component (rather than an enzyme or a part of the protein synthesis machinery like a ribosome), it resembles the action of the glycopeptide antibiotics vancomycin and teicoplanin. Glycopeptide antibiotics act by binding to the terminal d-alanyl-d-alanine of the pentapeptide peptidoglycan precursors. This binding inhibits the cleavage of the terminal d-alanine that provides the energy for formation of the bond creating the cross-bridge between different peptide side changes, as well as sterically inhibiting the transglycosylation necessary for peptidoglycan biosynthesis. In the most common form of vancomycin resistance found in gram-positive bacteria, an acquired set of genes sets in motion a process that results in the formation of pentapeptide precursors terminating in d-lactate, to which glycopeptides bind with roughly 1,000-fold lower affinity than to those terminating in d-alanine (3).

Since the above-described mechanism of resistance to glycopeptide antibiotics results from the acquisition of a resistance operon, it is not clear how relevant it is for comparison to polyene resistance in fungi. Perhaps more relevant is the recently described resistance to glycopeptides in Staphylococcus haemolyticus (10). This resistance, similar to polyene resistance, occurs as a result of serial passage on antimicrobial-containing plates and presumably as a result of repeated exposure to vancomycin in patients undergoing peritoneal dialysis for renal failure. Although the exact mechanism of this type of resistance is not clear, levels of resistance appears to correlate with substitutions in the bridge linking the peptide side chains. These alterations in bridge composition may inhibit cooperative binding of glycopeptides to the target, resulting in increased MICs of these antimicrobial agents.

(i) Mechanism of action.

Allylamines, such as terbinafine and naftifine, have been developed as a new class of ergosterol biosynthetic inhibitors that are functionally as well as chemically distinct from the other major classes of ergosterol-inhibiting antifungal agents (118, 119). Terbinafine (Fig. ​1) is highly effective against dermatophytes in vivo and in vitro. A recent study of terbinafine by the National Committee for Clinical Laboratory Standards M27 method showed that its geometric mean MIC against 179 clinical isolates of C. albicans was 1.2 μg/ml (61, 118). Furthermore, preliminary evidence from our group and from Ryder and coworkers indicates that terbinafine has good activity against at least some azole-resistant C. albicans strains (61, 118). By using the same assay system, terbinafine appears highly active against Cryptococcus neoformans (118). Studies investigating the efficacy of this agent against disseminated candidiasis in an animal model are under way.

Allylamines act by inhibiting early steps of ergosterol biosynthesis (Fig. ​2). This inhibition coincides with accumulation of the sterol precursor squalene and the absence of any other sterol intermediate (66), suggesting that allylamine inhibition of sterol synthesis occurs at the point of squalene epoxidation, a reaction catalyzed by squalene epoxidase. Studies with isolated squalene epoxidase indicate that it is the target for allylamine activity (118). Fungal cell death is related primarily to the accumulation of squalene rather than to ergosterol deficiency (118). High levels of squalene may increase membrane permeability (74), leading to disruption of cellular organization.

(ii) Mechanism of resistance to allylamines.

Although clinical failure has been observed in patients treated with terbinafine, allylamine resistance in association with clinical use of terbinafine and naftifine has not been found in human pathogenic fungi. However, with the increased use of this agent, resistance may be expected, since Vanden Bossche et al. (141) have reported a C. glabrata strain that became resistant to fluconazole and expressed cross-resistance to terbinafine. Other investigators report that CDR1 can use terbinafine as a substrate (122). The machinery to develop resistance to allylamines is therefore already present in some fungal species.

(a) Correlation with antibacterial resistance. Since allylamine-resistant fungi are as yet not well described, comparisons of resistance mechanisms are moot. It is worth noting, however, that the different sites of action of the azoles, polyenes, and allylamine resemble the sequential actions on cell wall synthesis exhibited by different antibacterial agents, including phosphomycin (a phosphoenolpyruvate analogue that acts at an early step in peptidoglycan synthesis) (64), penicillin (which acts at an intermediate step), and vancomycin (which acts at the final step in cross-linking). As in the study of cell wall synthesis in bacteria, some of the mechanisms of action of antifungal agents have been elucidated by analyzing the accumulation of specific precursors after exposure to the antibiotic. Since all of the antibiotics act at different steps of the same process, it is perhaps not surprising that specific mutations will result in cross-resistance to several of the compounds.

Compounds Active against Fungal Cell Walls

The fungal cell wall contains compounds, such as mannan, chitin, and α- and β-glucans, that are unique to the fungal kingdom. Since these components are not found elsewhere in nature, they have been identified as possible targets that provide selective toxicity advantages (48). Our knowledge of the cell wall composition of medically important fungi comes mainly from studies conducted with C. albicans. The cell wall of this yeast is a multilayered structure composed of chitin, β-glucan and mannoprotein, with the last two constituents making up to 80% of the wall mass (16, 110, 134). The outer layers are composed of mannan, mannoprotein, and β-(1,6)-glucan, while the inner layers are predominantly β-(1,3)-glucan and chitin with some mannoprotein (135).

A number of compounds that have the ability to affect the cell walls of fungi have been discovered and described over the past 30 years (48). We will concentrate in this review on glucan synthesis inhibitors only, since at least one antifungal agent that belongs to this class of compounds is being evaluated in clinical trials (MK-0991, being developed by Merck & Co.). Chitin synthesis inhibitors, such as nikkomycins, have been extensively investigated, but no product has been commercially developed.

Inhibitors of glucan synthesis.

Of the three groups of compounds (aculeacins, echinocandins, and papulacandins) that are specific inhibitors of fungal 3β-glucan synthase, only echinocandins (Fig. ​1) are being actively pursued in clinical trials to evaluate their safety, tolerability, and efficacy against candidiasis. Echinocandins, which are lipopeptides, have fungicidal activity both in vitro and in vivo against Candida and Aspergillus species (15, 138, 147).

(i) Mechanism of action.

β-Glucan inhibitors act as specific noncompetitive inhibitors of β-(1,3)-glucan synthetase, a large (210-kDa) integral membrane heterodimeric protein (48). Treatment of fungi with these compounds inhibits the synthesis of the structural glucan component without affecting nucleic acid or mannan synthesis (90, 137). Inhibitors of glucan synthesis also have secondary effects on other components of intact cells including a reduction in the ergosterol and lanosterol content and an increase in the chitin content of the cell wall (107). Inhibition of β-(1,3)-glucan synthetase results in cytological and ultrastructural changes in fungi characterized by growth as pseudohyphae, thickened cell wall, and buds failing to separate from mother cells. Cells also become osmotically sensitive (15, 139), with lysis being restricted largely to the growing tips of budding cells (12).

(ii) Mechanism of resistance to glucan synthesis inhibitors.

Since clinical use of glucan synthesis inhibitors has not occurred, resistant mutants resulting from clinical therapy are not available. Therefore, knowledge of mechanisms of glucan synthesis inhibitors resistance is based entirely on analysis of laboratory-derived mutants. The following discussion is based on the results of laboratory mutation experiments reported by Kurtz and coworkers (70, 71), who analyzed resistant mutants of S. cerevisiae. The target of lipopeptides, including echinocandins, is glucan synthase (a heterodimeric enzyme), which in S. cerevisiae is encoded by FKS1 and RHO1. S. cerevisiae also contains another gene, FKS2, which is highly homologous to FKS1. Mutations in the FKS1

1. Introduction

Pityriasis versicolor (PV) is a chronic cutaneous fungal infection caused by proliferation of lipophilic yeast (Malassezia species) in the stratum corneum [1,2]. The most common Malassezia species associated with PV is M. globosa, with M. sympodialis and M. furfur also frequently seen [3]. In most cases of PV, Malassezia, as a part of normal skin flora, are not pathogenic unless they assume a mycelial form [2]. This may be triggered by various factors, including humidity and high temperature, hyperhidrosis, familial susceptibility, and immunosuppression [1,2]. Consequently, PV occurs more frequently in tropical climates (as much as 40%) as compared to temperate climates [3]. PV is difficult to cure, as relapse following treatment can be as high as 80% within 2 years [4].

Patients with PV present with well demarcated round or oval macules on the trunk, neck, and upper arms where the density of sebaceous glands is high. These lesions often appear hyperpigmented on lighter skin types and hypopigmented in darker or tanned skin and can vary in color [5]. Smaller macules may have a powdery appearance due to flaking skin, although flaking may only manifest on the edges of larger lesions [2]. PV is generally asymptomatic, although some patients experience mild pruritus. By far, the greatest concern for patients lending to their seeking treatment is the unpleasant cosmetic appearance of the skin [2]. Unfortunately, altered pigmentation can persist following treatment. This is not often used as a criterion for treatment efficacy, with mycological cure (negative microscopy) and alleviation of physical symptoms such as lesion clearance, erythema, pruritus, and desquamation preferred.

Diagnosis of PV is confirmed by microscopy using skin scrapings from the borders of lesions, or, if this is not possible, obtaining samples using the transparent tape method. Wood’s light examination may also aid in diagnosis, with lesions appearing yellow or gold [2,6]. Topical antifungals are currently the first line of treatment for PV and systemic antifungals are recommended for severe or recalcitrant cases [7]. There are, however, many non-specific topical treatments that may be effective in treating PV [8,9]. In some cases, misdiagnosis may lead to inappropriate and ineffective treatment (e.g., antibiotics, corticosteroids) [5]. The focus of the present review is to highlight the clinical evidence supporting the use of topical and systemic antifungal medications in treating PV.

2. Topical Treatment for Pityriasis Versicolor

Effective topical treatment for PV includes creams, lotions, and shampoos. These are applied daily or twice daily for varying periods of time, quickly improving clinical symptoms. Patient compliance may be affected by multiple, laborious applications, or minor skin irritation. Non-specific topical treatments for PV do not act specifically against Malassezia species. Rather, they physically or chemically remove dead infected tissue [2]. Non-specific treatments shown to be effective in treating PV include selenium sulphide (lotion, cream, or shampoo), zinc pyrithione, propylene glycol, and Whitfield’s ointment [8,9].

There are multiple topical medications, such as bifonazole, clotrimazole, and miconazole, that have direct fungistatic activity and are shown to be effective in treating PV (for an extensive review, see Gupta et al., 2005 [9]). In many cases, these and non-specific agents are used in studies to demonstrate the comparable efficacy of the newer topical and oral antifungals [10,11,12,13]. For example, twice daily application of ciclopirox olamine cream 1% for 14 days was significantly more effective than 1% clotrimazole cream (mycological cure 77% vs. 45%, p ≤ 0.001) [14]. While evidence suggests that non-specific agents and older azoles can be effective in treating PV [7,8,9,10,11,12,13], the topical antifungals most extensively investigated recently are ketoconazole (Table 1) and terbinafine (Table 2).

Table 1. Clinical studies evaluating the efficacy of topical ketoconazole.

ReferenceDesignTreatment RegimenNo.Mycological CureComplete CureFollow-Up (Cure or Relapse)
Savin et al. 1986 [15] DB, R2% ketoconazole cream, 1×/day for 14 days5143/51 = 84% ***43/51 = 84% ***Cure rate: 38/48 = 79% (12 months)
Placebo cream5011/50 = 22%5/50 = 10%16/48 = 33% (24 months)
Balwada et al. 1996 [12]DB, R2% ketoconazole cream, 1×/day for 14 days2018/20 = 90%18/20 = 90%Cure rate: 16/16 = 100% (8 weeks)
1% clotrimazole cream2017/20 = 85%16/20 = 80%16/16 = 100% (8 weeks)
Chopra et al. 2000 [16]R2% ketoconazole cream, 1×/day for 14 days2522/25 = 88%20/25 = 80%Relapse: 3 patients (3 months)
1% terbinafine cream2524/25 = 96%24/25 = 96%2 patients (3 months)
Lange et al. 1998 [17]DB, R2% ketoconazole shampoo, 1×/day, for 3 days106At Day 31, 89/106 = 84% **At Day 31, 77/106 = 73% **-
2% ketoconazole shampoo, 1 day, placebo days 2, 310379/101 = 78% **71/103 = 69% **-
Placebo 1×/day, for 3 days10311/103 = 11%5/103 = 5%-
Aggarwal et al. 2003 [11]R2% ketoconazole shampoo, 1×/week for 3 weeks20At 4 weeks, 19/20 = 95%-Relapse: 1 patient (3 months)
2.5% selenium sulphide shampoo2017/20 = 85%-2 patients (3 months)
Rathi 2003 [18]O2% ketoconazole shampoo, 1×/day, for 3 days30At Day 31, 27/30 = 90%--
Rigopoulos et al. 2007 [19]DB, R2% ketoconazole shampoo, 1×/day for 14 days26At Day 28, 21/26 = 81%At Day 28, 21/26 = 81%-
1% flutrimazole shampoo2922/29 = 76%22/29 = 76%-
Di Fonzo et al. 2008 [20]R1% ketoconazole foam, 1×/day for 14 days22At 5 weeks, 18/18 = 100%At 5 weeks, 5/18 = 28%Complete cure rate: 9/11 = 82% (3 months)
2% ketoconazole cream2419/19 = 100%9/19 = 47%12/13 = 92% (3 months)
Cantrell et al. 2014 [21]O2% ketoconazole foam, 2×/day for 14 days11At 4 weeks, 6/11 = 55%-Relapse: 1 patient (4 weeks)
Shi et al. 2014 [22]DB, R2% ketoconazole cream + 0.1% adapalene gel, 1×/day for 14 days50At 4 weeks, 46/50 = 92% **--
2% ketoconazole cream, 2×/day for 14 days50At 4 weeks, 36/50 = 72%--

Table 2. Clinical studies evaluating the efficacy of topical terbinafine.

ReferenceDesignTreatment RegimenNo.Mycological CureComplete CureFollow-Up (Cure or Relapse)
Kagawa 1989 [23]O1% terbinafine cream, 2×/day for 14 days8778/87 = 90%--
Aste et al. 1991 [10]SB, R1% terbinafine cream, 2×/day up to 4 weeks20At 4 weeks, 20/20 = 100%At 4 weeks, 20/20 = 100%-
1% bifonazole cream2019/20 = 95%19/20 = 95%-
Faergemann et al. 1997 [24]DB, R1% terbinafine emulsion gel, 1×/day, for 7 days28At 8 weeks, 21/28 = 75% ***At 8 weeks, 21/28 = 75% ***-
Placebo gel294/29 = 14%4/29 = 14%-
Vermeer et al. 1997 [25]DB, R1% terbinafine solution, 2×/day for 7 days76At 8 weeks, 62/76 = 81% ***At 8 weeks, 36/76 = 47%-
Placebo3414/34 = 41%10/34 = 29%-
Savin et al. 1999 [26]DB, R1% terbinafine solution, 2×/day for 7 days10246/96 = 48% *-Myc. cure rate: 69/85 = 81% * (8 weeks)
Placebo solution5014/46 = 30%-13/43 = 30% (8 weeks)
Budimulja et al. 2002 [27]DB, R1% terbinafine solution, 2×/day for 7 days192At 2 weeks, 108/192 = 56% ***-Relapse (from week 4 to 8): 2 patients Myc. cure rate (8 weeks):123/192 = 64% ***

0 thoughts on “Itraconazole Synthesis Essay”

    -->

Leave a Comment

Your email address will not be published. Required fields are marked *